S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
Best Bear Market Funds: Top 3 Investment Options to Consider
How and When to Roll Your Options Positions?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
Best Bear Market Funds: Top 3 Investment Options to Consider
How and When to Roll Your Options Positions?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
Best Bear Market Funds: Top 3 Investment Options to Consider
How and When to Roll Your Options Positions?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
Best Bear Market Funds: Top 3 Investment Options to Consider
How and When to Roll Your Options Positions?
NASDAQ:STIM

Neuronetics (STIM) Stock Price, News & Analysis

$4.80
+0.04 (+0.84%)
(As of 03/27/2024 ET)
Today's Range
$4.55
$4.90
50-Day Range
$2.79
$4.80
52-Week Range
$1.03
$4.99
Volume
140,664 shs
Average Volume
254,494 shs
Market Capitalization
$142.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00

Neuronetics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
66.7% Upside
$8.00 Price Target
Short Interest
Healthy
0.18% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.47mentions of Neuronetics in the last 14 days
Based on 14 Articles This Week
Insider Trading
Selling Shares
$519,307 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.92) to ($0.62) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.01 out of 5 stars

Medical Sector

395th out of 939 stocks

Surgical & Medical Instruments Industry

48th out of 99 stocks

STIM stock logo

About Neuronetics Stock (NASDAQ:STIM)

Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

STIM Stock Price History

STIM Stock News Headlines

Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
STIM Apr 2024 5.000 put
Neuronetics Q4 2023 Earnings Preview
See More Headlines
Receive STIM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neuronetics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/05/2024
Today
3/28/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:STIM
Employees
203
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.00
High Stock Price Target
$8.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+66.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-30,190,000.00
Pretax Margin
-42.31%

Debt

Sales & Book Value

Annual Sales
$71.35 million
Book Value
$1.18 per share

Miscellaneous

Free Float
28,209,000
Market Cap
$142.85 million
Optionable
Optionable
Beta
2.38
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

STIM Stock Analysis - Frequently Asked Questions

Should I buy or sell Neuronetics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Neuronetics in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" STIM shares.
View STIM analyst ratings
or view top-rated stocks.

What is Neuronetics' stock price target for 2024?

2 brokers have issued 1 year price targets for Neuronetics' shares. Their STIM share price targets range from $8.00 to $8.00. On average, they anticipate the company's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 66.7% from the stock's current price.
View analysts price targets for STIM
or view top-rated stocks among Wall Street analysts.

How have STIM shares performed in 2024?

Neuronetics' stock was trading at $2.90 at the beginning of the year. Since then, STIM stock has increased by 65.5% and is now trading at $4.80.
View the best growth stocks for 2024 here
.

Are investors shorting Neuronetics?

Neuronetics saw a drop in short interest in March. As of March 15th, there was short interest totaling 53,200 shares, a drop of 64.9% from the February 29th total of 151,700 shares. Based on an average trading volume of 204,300 shares, the short-interest ratio is currently 0.3 days.
View Neuronetics' Short Interest
.

When is Neuronetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our STIM earnings forecast
.

How were Neuronetics' earnings last quarter?

Neuronetics, Inc. (NASDAQ:STIM) issued its quarterly earnings results on Tuesday, March, 5th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.07. The firm had revenue of $20.31 million for the quarter, compared to analysts' expectations of $19.73 million. Neuronetics had a negative net margin of 42.31% and a negative trailing twelve-month return on equity of 72.76%. During the same quarter last year, the firm earned ($0.30) EPS.

What guidance has Neuronetics issued on next quarter's earnings?

Neuronetics updated its first quarter 2024 earnings guidance on Wednesday, March, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $16.7 million-$17.7 million, compared to the consensus revenue estimate of $17.0 million.

What other stocks do shareholders of Neuronetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neuronetics investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Novavax (NVAX), Gilead Sciences (GILD), iBio (IBIO), Onconova Therapeutics (ONTX), Pfizer (PFE), Tonix Pharmaceuticals (TNXP), Vaxart (VXRT) and Acasti Pharma (ACST).

When did Neuronetics IPO?

Neuronetics (STIM) raised $75 million in an initial public offering on Thursday, June 28th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Piper Jaffray and William Blair served as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers.

Who are Neuronetics' major shareholders?

Neuronetics' stock is owned by many different institutional and retail investors. Top institutional investors include Cannell Capital LLC (9.57%), Balyasny Asset Management L.P. (4.90%), Kent Lake Capital LLC (3.86%), Millrace Asset Group Inc. (2.51%), Thompson Siegel & Walmsley LLC (0.65%) and Dimensional Fund Advisors LP (0.40%). Insiders that own company stock include Bruce Joseph Shook, Cannell Capital Llc, Keith J Sullivan, Paul Liberman, Robert Cascella, Sheryl L Conley, Stephen Furlong and William Andrew Macan.
View institutional ownership trends
.

How do I buy shares of Neuronetics?

Shares of STIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:STIM) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners